MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 16, 2005; DOI: 10.1124/mol.105.012997


0026-895X/05/6803-660-669$20.00
Mol Pharmacol 68:660-669, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.012997v1
68/3/660    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bae, E. J.
Right arrow Articles by Kim, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bae, E. J.
Right arrow Articles by Kim, S. G.

Enhanced CCAAT/Enhancer-Binding Protein {beta}-Liver-Enriched Inhibitory Protein Production by Oltipraz, Which Accompanies CUG Repeat-Binding Protein-1 (CUGBP1) RNA-Binding Protein Activation, Leads to Inhibition of Preadipocyte Differentiation

Eun Ju Bae, and Sang Geon Kim

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea

The CCAAT/enhancer-binding protein (C/EBP) {beta}-isoforms liver-enriched activator protein (LAP) and truncated dominant-negative liver-enriched inhibitory protein (LIP) differentially regulate adipogenesis. We previously demonstrated that oltipraz (5-[2-pyrazinyl]-4-methyl-1,2-dithiol-3-thione), a cancer-chemopreventive agent, promotes C/EBP{beta}-LAP activation in hepatocytes. This study investigated whether oltipraz affects adipocyte differentiation and, if so, the molecular basis for the alterations in adipogenesis. The expression of LIP notably increased 6 to 48 h after oltipraz treatment of 3T3-L1 preadipocytes, whereas that of LAP was minimally changed. Oltipraz treatment ~3-fold elevated the ratio of LIP to LAP. Immunoblot, gel-shift, and Southwestern analyses revealed that oltipraz enhanced the levels of nuclear LIP and LAP and their binding to the C/EBP-binding site. Cotransfection of predipocytes with the plasmid encoding LIP interfered with LAP-mediated luciferase expression, confirming the inhibitory role of LIP in gene expression. Likewise, LAP-mediated luciferase gene transactivation was inhibited by oltipraz, as was observed by cotransfection of a dominant-negative mutant form of C/EBP. Oltipraz enhanced cytoplasmic translocation and RNA binding of CUG repeat-binding protein-1 (CUGBP1) but not calreticulin, another RNA-binding protein that interacts with C/EBP{beta} mRNA. When 3T3-L1 preadipocytes were induced to differentiate by exposure to 3-isobutyl-1-methylxanthine, dexamethasone, and insulin, oltipraz markedly inhibited hormone-induced adipocyte differentiation. In primary cultured rat preadipocytes, oltipraz enhanced LIP production and inhibited adipocyte differentiation. In conclusion, oltipraz inhibits adipogenesis by promoting LIP production and activation, and the enhanced LIP production accompanies cytoplasmic translocation of CUGBP1 and its binding to the GC-rich region of C/EBP{beta} mRNA. Our finding holds significance in that adipogenesis can be pharmacologically controlled by LIP production.


Received March 17, 2005; accepted June 16, 2005

Address correspondence to: Dr. Sang Geon Kim, College of Pharmacy, Seoul National University, Sillim-dong, Kwanak-gu, Seoul 151-742, South Korea. E-mail: sgk{at}snu.ac.kr




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
E. J. Bae, Y. M. Yang, and S. G. Kim
Abrogation of Hyperosmotic Impairment of Insulin Signaling by a Novel Class of 1,2-Dithiole-3-thiones through the Inhibition of S6K1 Activation
Mol. Pharmacol., May 1, 2008; 73(5): 1502 - 1512.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Dudaronek, S. A. Barber, and J. E. Clements
CUGBP1 Is Required for IFNbeta-Mediated Induction of Dominant-Negative CEBPbeta and Suppression of SIV Replication in Macrophages
J. Immunol., December 1, 2007; 179(11): 7262 - 7269.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Karagiannides, T. Thomou, T. Tchkonia, T. Pirtskhalava, K. E. Kypreos, A. Cartwright, G. Dalagiorgou, T. L. Lash, S. R. Farmer, N. A. Timchenko, et al.
Increased CUG Triplet Repeat-binding Protein-1 Predisposes to Impaired Adipogenesis with Aging
J. Biol. Chem., August 11, 2006; 281(32): 23025 - 23033.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
M. S. Ko, S. J. Lee, J. W. Kim, J. W. Lim, and S. G. Kim
DIFFERENTIAL EFFECTS OF THE OXIDIZED METABOLITES OF OLTIPRAZ ON THE ACTIVATION OF CCAAT/ENHANCER BINDING PROTEIN-{beta} AND NF-E2-RELATED FACTOR-2 FOR GSTA2 GENE INDUCTION
Drug Metab. Dispos., August 1, 2006; 34(8): 1353 - 1360.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics